U.S. FDA APPROVES WELIREG® (BELZUTIFAN) PLUS LENVIMA® (LENVATINIB) FOR CERTAIN PREVIOUSLY TREATED ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA WITH A CLEAR CELL COMPONENT (CCRCC)

Reuters · 1d ago

Please log in to view news